Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

BACTI-B.ST SE Equity

Bactiguard Holding AB
Nasdaq Stockholm+ CompareTear sheet →
Health Care · FY ends Dec 31
SEK 15.00
-0.20 (-1.32%)
SEK · as of 2026-08-20 · marketstack
5 registered studies · 0 active

Studies where BACTI-B.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

5 interventional

government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUsNCT04242706VAP incidenceRandomized · Quadruple-masked · PreventionPhase 4CompletedDevice: ETTEvac, BIP ETTEvacVentilator-associated Pneumonia3232020-05-08actual2021-01-20
BIP Foley in Prevention of CAUTI at Rehab StationNCT02808000Incidence of CAUTIRandomized · Single-masked · PreventionPhase 4CompletedDevice: BIP Foley (latex) or BIP Foley -silicone, Standard catheterComplications; Catheter, Urinary Infection or Inflammation142020-03-09actual2021-01-22
BIP CVC in Access Center at Danderyd Hospital, Stockholm, SwedenNCT03976557Number of patients with catheter related complicationsRandomized · Open-label · PreventionNot applicableTerminatedsponsor's stated reason: Due to Corona/Covid19 pandemicDevice: BIP CVC, Standard CVCVascular Access Complication, Catheter-Related Infections, Catheter Thrombosis, Catheter Blockage, Catheter Complications, Catheter Site Discomfort, Catheter Bacteraemia192019-12-18actual2021-01-22
BIP CVC Clinical Safety and Performance StudyNCT02811380Assessment of safety by evaluation of CVC related adverse events and any problems in post operative course.Randomized · Single-masked · Supportive carePhase 4CompletedDevice: BIP CVC, Uncoated Standard CVCSurgery, Central Line Associated Blood Stream Infections (CLABSI)36Jan 2015actual2016-06-23
BIP ETT Clinical Tolerability, Safety and Performance StudyNCT01682486Tolerability assessment by using a symptom questionnaire (QLQ-H&N35) before and after surgery. Evaluation of tracheal mucosa directly during surgery and after the end of study by using photos.Randomized · Single-masked · Supportive careNot applicableCompletedDevice: BIP ETT (Bactiguard) · Procedure: Standard ETTEndotracheal Intubation During Surgery, Hospital Acquired Infections30Jan 2013actual2016-06-20

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-21